Nanoscale Coordination Polymers Codeliver Chemotherapeutics and siRNAs to Eradicate Tumors of Cisplatin-Resistant Ovarian Cancer.

Drug resistance impedes the successful treatment of many types of cancers, especially ovarian cancer (OCa). To counter this problem, we developed novel long-circulating, self-assembled core-shell nanoscale coordination polymer (NCP) nanoparticles that efficiently deliver multiple therapeutics with different mechanisms of action to enhance synergistic therapeutic effects. These NCP particles contain high payloads of chemotherapeutics cisplatin or cisplatin plus gemcitabine in the core and pooled siRNAs that target multidrug resistant (MDR) genes in the shell. The NCP particles possess efficient endosomal escape via a novel carbon dioxide release mechanism without compromising the neutral surface charge required for long blood circulation and effectively downregulate MDR gene expression in vivo to enhance chemotherapeutic efficacy by several orders of magnitude. Even at low doses, intraperitoneal injections of nanoparticles led to effective and long-lasting tumor regression/eradication in subcutaneous and intraperitoneal xenograft mouse models of cisplatin-resistant OCa. By silencing MDR genes in tumors, self-assembled core-shell nanoparticles promise a more effective chemotherapeutic treatment for many challenging cancers.

[1]  A. Tinker,et al.  "Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit? , 2014, Gynecologic oncology.

[2]  Gang Zheng,et al.  Nanoparticle-enabled, image-guided treatment planning of target specific RNAi therapeutics in an orthotopic prostate cancer model. , 2014, Small.

[3]  B. Monk,et al.  Latest research and treatment of advanced-stage epithelial ovarian cancer , 2013, Nature Reviews Clinical Oncology.

[4]  P. Krammer,et al.  Tumor Immunology , 2018, Medical Immunology.

[5]  P B Laub,et al.  Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells , 2005, British Journal of Cancer.

[6]  Enzo Di Fabrizio,et al.  Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy , 2012, International journal of nanomedicine.

[7]  U. Menon,et al.  Ovarian cancer screening—Current status, future directions☆ , 2014, Gynecologic oncology.

[8]  Leaf Huang,et al.  Non-viral nanocarriers for siRNA delivery in breast cancer. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[9]  Michael S. Goldberg,et al.  Cosilencing of PKM-2 and MDR-1 Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian Cancer , 2015, Molecular Cancer Therapeutics.

[10]  Alexander V Kabanov,et al.  Nanocarriers for delivery of platinum anticancer drugs. , 2013, Advanced drug delivery reviews.

[11]  K. Ushijima Treatment for Recurrent Ovarian Cancer—At First Relapse , 2009, Journal of oncology.

[12]  M. Eblan,et al.  Clinical Translation of Nanomedicine. , 2015, Chemical reviews.

[13]  Lily Yang,et al.  Targeted delivery of siRNA-generating DNA nanocassettes using multifunctional nanoparticles. , 2013, Small.

[14]  S. Inoue,et al.  Curcumin Targeted, Polymalic Acid-Based MRI Contrast Agent for the Detection of Aβ Plaques in Alzheimer's Disease. , 2015, Macromolecular bioscience.

[15]  Z. Duan,et al.  MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer , 2015, Scientific Reports.

[16]  Warren C W Chan,et al.  Strategies for the intracellular delivery of nanoparticles. , 2011, Chemical Society reviews.

[17]  Gert Storm,et al.  Endosomal escape pathways for delivery of biologicals. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[18]  G. Mills,et al.  Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth , 2011, Nature Medicine.

[19]  Kenneth P. Nephew,et al.  Rethinking ovarian cancer: recommendations for improving outcomes , 2011, Nature Reviews Cancer.

[20]  Gang Zheng,et al.  Cancer nanomedicine: addressing the dark side of the enhanced permeability and retention effect. , 2015, Nanomedicine.

[21]  Chad A. Mirkin,et al.  Gene regulation with polyvalent siRNA-nanoparticle conjugates. , 2009, Journal of the American Chemical Society.

[22]  Taeghwan Hyeon,et al.  Multifunctional tumor pH-sensitive self-assembled nanoparticles for bimodal imaging and treatment of resistant heterogeneous tumors. , 2014, Journal of the American Chemical Society.

[23]  Lily Yang,et al.  Targeted Delivery with Imaging Assessment of siRNA Expressing Nanocassettes into Cancer. , 2016, Methods in molecular biology.

[24]  Wenbin Lin,et al.  Self-assembled core-shell nanoparticles for combined chemotherapy and photodynamic therapy of resistant head and neck cancers. , 2015, ACS nano.

[25]  Sarah Seifert,et al.  Image-based analysis of lipid nanoparticle–mediated siRNA delivery, intracellular trafficking and endosomal escape , 2013, Nature Biotechnology.

[26]  Chad A. Mirkin,et al.  Spherical Nucleic Acid Nanoparticle Conjugates as an RNAi-Based Therapy for Glioblastoma , 2013, Science Translational Medicine.

[27]  L. Kèlland,et al.  The resurgence of platinum-based cancer chemotherapy , 2007, Nature Reviews Cancer.

[28]  H. Hollema,et al.  Cell biological markers of drug resistance in ovarian carcinoma. , 1995, Gynecologic oncology.

[29]  M. Gottesman Mechanisms of cancer drug resistance. , 2002, Annual review of medicine.

[30]  Leaf Huang,et al.  Pharmacokinetics and biodistribution of nanoparticles. , 2008, Molecular pharmaceutics.

[31]  Warren C W Chan,et al.  The effect of nanoparticle size, shape, and surface chemistry on biological systems. , 2012, Annual review of biomedical engineering.

[32]  Joseph M. DeSimone,et al.  Strategies in the design of nanoparticles for therapeutic applications , 2010, Nature Reviews Drug Discovery.

[33]  F. Muggia Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. , 2009, Gynecologic oncology.

[34]  R. Mach,et al.  Using SV119‐Gold Nanocage Conjugates to Eradicate Cancer Stem Cells Through a Combination of Photothermal and Chemo Therapies , 2014, Advanced healthcare materials.

[35]  Taeghwan Hyeon,et al.  pH-sensitive nanoformulated triptolide as a targeted therapeutic strategy for hepatocellular carcinoma. , 2014, ACS nano.

[36]  George A. Calin,et al.  RNA interference in the clinic: challenges and future directions , 2011, Nature Reviews Cancer.

[37]  William Y. Kim,et al.  Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[38]  Wenbin Lin,et al.  Self-assembled nanoscale coordination polymers carrying siRNAs and cisplatin for effective treatment of resistant ovarian cancer. , 2015, Biomaterials.

[39]  John J. Rossi,et al.  The promises and pitfalls of RNA-interference-based therapeutics , 2009, Nature.

[40]  Christopher Poon,et al.  Self-assembled nanoscale coordination polymers with trigger release properties for effective anticancer therapy , 2014, Nature Communications.

[41]  R. Agarwal,et al.  Ovarian cancer: strategies for overcoming resistance to chemotherapy , 2003, Nature Reviews Cancer.

[42]  A. Fire,et al.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.

[43]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[44]  Bulent Ozpolat,et al.  Preclinical and clinical development of siRNA-based therapeutics. , 2015, Advanced drug delivery reviews.

[45]  J. Ljubimova,et al.  Nanomedicine therapeutic approaches to overcome cancer drug resistance. , 2013, Advanced drug delivery reviews.

[46]  D. Dykxhoorn,et al.  Breaking down the barriers: siRNA delivery and endosome escape , 2010, Journal of Cell Science.

[47]  P. Kruk,et al.  The genesis of RNA interference, its potential clinical applications, and implications in gynecologic cancer. , 2005, Gynecologic oncology.

[48]  E. Wang,et al.  Nanoparticle delivery of chemosensitizers improve chemotherapy efficacy without incurring additional toxicity. , 2015, Nanoscale.

[49]  A. Malpica,et al.  Ovarian low-grade serous carcinoma: a comprehensive update. , 2012, Gynecologic oncology.